Botanix PharmaceuticalsBXPHF EV-to-FCF is -0.74 as of Jul. 05, 2026. The stock has 7 warning signs investors should review. Among 331 Biotechnology companies, Botanix Pharmaceuticals ranks worse than 302114.5% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Botanix Pharmaceuticals's Enterprise Value is $38.30 Mil.
Botanix Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was $-51.51 Mil. Therefore, Botanix Pharmaceuticals's EV-to-FCF for today is -0.74.
The historical rank and industry rank for Botanix Pharmaceuticals's EV-to-FCF or its related term are showing as below:
BXPHF'
s EV-to-FCF Range Over the Past 10 Years
Min: -7.46 Med: -2.37 Max: -0.03
Current: -0.71
During the past 13 years, the highest EV-to-FCF of Botanix Pharmaceuticals was -0.03. The lowest was -7.46. And the median was -2.37.
BXPHF's EV-to-FCF is ranked worse than 100% of 331
companies
in the Biotechnology industry
Industry Median: 16.48
vs BXPHF: -0.71
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Botanix Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
Botanix Pharmaceuticals's share price for today is $0.0114.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Botanix Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.030.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Botanix Pharmaceuticals's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Botanix Pharmaceuticals EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Botanix Pharmaceuticals's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Botanix Pharmaceuticals's EV-to-FCF falls into.
Botanix Pharmaceuticals's current Enterprise Value is $38.30 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Botanix Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was $-51.51 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Botanix Pharmaceuticals (BXPHF) has a EV-to-FCF of -0.74 as of Jul. 05, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Botanix Pharmaceuticals and its competitors. According to the industry distribution chart, Botanix Pharmaceuticals ranks #999999 out of 331 companies in the Biotechnology industry.
Is Botanix Pharmaceuticals' EV-to-FCF too high?
Botanix Pharmaceuticals' current EV-to-FCF is -0.74. Based on the distribution chart, Botanix Pharmaceuticals ranks #999999 out of 331 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Botanix Pharmaceuticals' EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Botanix Pharmaceuticals ranks #999999 out of 331 companies for EV-to-FCF. This places Botanix Pharmaceuticals in the lower half of its industry. The industry median EV-to-FCF is 16.48. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 16.48, based on 331 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Botanix Pharmaceuticals and its competitors. For the Biotechnology industry, the median EV-to-FCF is 16.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Botanix Pharmaceuticals's current EV-to-FCF is -0.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Botanix Pharmaceuticals stock overvalued right now?
Botanix Pharmaceuticals (BXPHF) has a current EV-to-FCF of -0.74. The current EV-to-FCF is -0.74. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Botanix Pharmaceuticals (BXPHF), the current EV-to-FCF is -0.74 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Botanix Pharmaceuticals Ltd is a dermatology company. The company focuses on developing safe and effective topical treatments for serious skin conditions. It has an exclusive license to use a proprietary drug delivery system for all skin diseases. The company's product pipeline includes BTX 1503 - Moderate to Severe Acne, BTX 1204 - Atopic Dermatitis, BTX 1702 - Rosacea, Sofdra - Axillary Hyperhidrosis, and others. The majority of Revenue is derived from Australia.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BXPHF has been successfully added to your 